Frontline Therapy Insights in Multiple Myeloma

The discussion reveals that Darzalex is currently the leading treatment for newly diagnosed multiple myeloma, with significant adoption of a four-drug induction regimen among transplant-eligible patients, showing over 50% utilization in the US and up to 70% in Europe. However, there remains potential growth in the treatment of transplant-ineligible patients, where usage is approximately 30% in the US academic centers and around 20% in Europe. Maintenance therapy also shows room for improvement, with current usage ranging from 15% to 30%, suggesting a critical need for more compelling data to advocate for extended maintenance treatments. Future trials are anticipated to provide more clarity on the efficacy of various maintenance strategies, influencing broader implementation in treatment plans.